Non-cystic Fibrosis Bronchiectasis Clinical Trial
Official title:
Bronchoscopic Derived Bronchoalveolar Lavage Procalcitonin as a Marker of Severity of Non-cystic Fibrosis Bronchiectasis in Children
The aim of this study is to evaluate the role of procalcitonin in bronchoalveolar lavage as a biomarker for assessment of severity of non-CF bronchiectasis in children in correlation with other markers (functional and radiological severity )
• The severity of bronchiectasis will be assessed using forced expiratory volume in 1s (FEV1), and bronchiectasis severity scores which included bronchiectasis severity index (BSI) , FEV1, chronic colonization, extension of lobes and dyspnea which were performed to assess non-CF bronchiectasis patients. BSI score - This score incorporates 9 variables. The total score is calculated by summing the scores for each variable and can range from 0 to 26 points. According to the overall score, patients are classified into three classes: patients with low BSI score (0---4 points), intermediate BSI score (5---8 points), high BSI score (≥9 points) - chest X ray and HRCT of the chest: to assess the radiological severity of bronchiectasis using the radiological findings will be measured by assessing the most recent chest X ray and HRCT of the chest performed in the last six months using Bhalla score(10) - Culture and sensitivity from bronchoalveolar lavage for isolation of pseudomonas aeruginosa and any other organism. - Sputum procalcitonin level was measured in BAL samples using bronchoscopy. - Bronchoscopy: would be undertaken when the children were in a stable clinical condition as part of their annual review ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01792440 -
The Sputum Colour Chart as a Predictor of Lung Inflammation and Proteolysis in Non-cystic Fibrosis Bronchiectasis
|
N/A | |
| Active, not recruiting |
NCT05523180 -
A Study to Evaluate the Effect of Probiotic Supplement on Quality of Life
|
N/A | |
| Completed |
NCT03218917 -
Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis
|
Phase 2 | |
| Completed |
NCT05495243 -
Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-CF Bronchiectasis With Excess Mucus and Cough
|
Phase 2 | |
| Recruiting |
NCT06237348 -
Simeox Therapy at Home Versus Standard of Care in NCFB Patients With CMH
|
N/A | |
| Completed |
NCT03056326 -
A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects
|
Phase 1 | |
| Not yet recruiting |
NCT02614300 -
The Role of Pulmonary Rehabilitation and Airways Clearance Techniques in the Multidisciplinary Management of Non CF Bronchiectasis
|
N/A | |
| Recruiting |
NCT04322929 -
Roflumilast in Non-CF Bronchiectasis Study (2019)
|
Phase 2 | |
| Completed |
NCT05369624 -
Exercise Capacity in Non-cystic Fibrosis Bronchiectasis After a Pulmonary Rehabilitation Home-based Program
|
N/A | |
| Completed |
NCT04010799 -
A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis
|
Phase 1 | |
| Completed |
NCT03428334 -
Roflumilast in Non-CF Bronchiectasis Study
|
Phase 2 | |
| Completed |
NCT04656275 -
A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation
|
Phase 1 | |
| Not yet recruiting |
NCT06151366 -
Early Detection of Pulmonary Exacerbations in Non-cystic Fibrosis Bronchiectasis
|
||
| Completed |
NCT02081963 -
Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis
|
Phase 4 | |
| Completed |
NCT02883101 -
The Effects of Pulmonary Rehabilitation in Patients With Non-cystic Fibrosis Bronchiectasis
|
N/A | |
| Completed |
NCT01792427 -
Mortality in Non-cystic Fibrosis Bronchiectasis
|
N/A | |
| Recruiting |
NCT04278040 -
Inhalations of Ultra-low Doses of Melphalan for the Treatment of Non-cystic Fibrosis Bronchiectasis
|
Phase 2 | |
| Active, not recruiting |
NCT05006573 -
Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis
|
Phase 3 | |
| Recruiting |
NCT05860803 -
Breathing Training and Exercise Capacity in Non-CFB
|
N/A | |
| Recruiting |
NCT05616221 -
Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection
|
Phase 2 |